Daniel Habermehl

Heidelberg University, University Hospital Heidelberg

Papers

2

Total Citations

168

H-Index

2

About

Daniel Habermehl is a leading figure in radiation oncology, with a primary focus on stereotactic body radiotherapy (SBRT) for metastatic disease and precision particle therapy. His most impactful contribution is the landmark SBRT database initiative of the German Society for Radiation Oncology (DEGRO), which analyzed patterns of care and outcomes for 474 patients with 623 liver oligometastases. This study, cited over 150 times, established critical factors influencing local tumor control and overall survival, helping to standardize SBRT for liver metastases across Germany. Dr. Habermehl has also advanced the technical accuracy of particle radiation therapy, investigating inter- and intrafraction positioning errors with commercial thermoplastic masks for head-and-neck, brain, and skull base tumors. His work on image-guided particle therapy has directly improved treatment precision and patient safety. Through these contributions, he has shaped clinical guidelines for SBRT in oligometastatic disease and enhanced the reliability of high-precision radiotherapy, making him a key researcher in modern radiation oncology.

Research Focus

Key Achievements

2
H-Index
2
Papers
168
Total Citations
84
Avg Citations/Paper
🏆 Most Cited Paper
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
152 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 24
🏛 Institutions: Heidelberg University, University Hospital Heidelberg

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago